phalanx biotech
肝癌甲基化
DNA Methylation Biomarkers as Prediction Tools for Therapeutic Response and Prognosis in Intermediate-Stage Hepatocellular Carcinoma
Lu, C.-Y., Hsiao, C.-Y., Peng, P.-J., Huang, S.-C., Chuang, M.-R., Su, H.-J., & Huang, K.-W. (2023). Cancers, 15(18), 4465. https://doi.org/10.3390/cancers15184465
Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma
Lu, C.-Y., Chen, S.-Y., Peng, H.-L., Kan, P.-Y., Chang, W.-C., & Yen, C.-J. (2017). Oncotarget, 8(4), 6406–6418. https://doi.org/10.18632/oncotarget.14248
Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma
Lu, C.-Y., Lin, K.-Y., Tien, M.-T., Wu, C.-T., Uen, Y.-H., & Tseng, T.-L. (2013). Genes, Chromosomes & Cancer, 52(7), 636–643. https://doi.org/10.1002/gcc.22067
Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma
Lu, C., Hsieh, S., Lu, Y., Wu, C., Chen, L., Lo, S., ... Chang, Y. (2009). Genes, Chromosomes & Cancer, 48(12), 1057–1068. https://doi.org/10.1002/gcc.20719